{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:18:06Z","timestamp":1760242686108,"version":"build-2065373602"},"reference-count":25,"publisher":"BMJ","issue":"3","funder":[{"name":"Funding for this research was provided by Recro Pharma, Inc., Malvern, PA."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":[],"accepted":{"date-parts":[[2018,12,6]]},"published-print":{"date-parts":[[2019,3]]},"abstract":"\n Background and objectives<\/jats:title>\n To describe the safety and tolerability of intravenous meloxicam compared with placebo across all phase II\/III clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Safety data and opioid use from subjects with moderate to severe postoperative pain who received \u22651 dose of intravenous meloxicam (5\u201360 mg) or placebo in 1 of 7 studies (4 phase II; 3 phase III) were pooled. Data from intravenous meloxicam 5 mg, 7.5 mg and 15 mg groups were combined (low-dose subset).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1426 adults (86.6% white; mean age: 45.8 years) received \u22651 dose of meloxicam IV; 517 (77.6% white; mean age: 46.7 years) received placebo. The incidence of treatment-emergent adverse events (TEAEs) in intravenous meloxicam and placebo-treated subjects was 47% and 57%, respectively. The most commonly reported TEAEs across treatment groups (intravenous meloxicam 5\u201315 mg, 30 mg, 60 mg and placebo, respectively) were nausea (4.3%, 20.8%, 5.8% and 25.3%), headache (1.5%, 5.6%, 1.6% and 10.4%), vomiting (2.8%, 4.6%, 1.6% and 7.4%) and dizziness (0%, 3.5%, 1.1% and 4.8%). TEAE incidence was generally similar in subjects aged >65 years with impaired renal function and the general population. Similar rates of cardiovascular events were reported between treatment groups. One death was reported (placebo group; unrelated to study drug). There were 35 serious adverse events (SAEs); intravenous meloxicam 15 mg (n=5), intravenous meloxicam 30 mg (n=15) and placebo (n=15). The SAEs in meloxicam-treated subjects were determined to be unrelated to study medication. Six subjects withdrew due to TEAEs, including three treated with intravenous meloxicam (rash, localized edema and postprocedural pulmonary embolism). In trials where opioid use was monitored, meloxicam reduced postoperative rescue opioid use.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Intravenous meloxicam was generally well tolerated in subjects with moderate to severe postoperative pain.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n NCT01436032<\/jats:ext-link>, NCT00945763<\/jats:ext-link>, NCT01084161<\/jats:ext-link>, NCT02540265<\/jats:ext-link>, NCT02678286<\/jats:ext-link>, NCT02675907<\/jats:ext-link> and NCT02720692<\/jats:ext-link>.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rapm-2018-100184","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T05:45:36Z","timestamp":1560231936000},"page":"360-368","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects"],"prefix":"10.1136","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct01436032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00945763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02540265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02678286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02675907","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00945763","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01436032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01436032","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02675907","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02678286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01084161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02678286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02675907","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02720692","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eugene R","family":"Viscusi","sequence":"first","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong J","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Stony Brook University, Stony Brook, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Bergese","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Singla","sequence":"additional","affiliation":[{"name":"Lotus Clinical Research, Pasadena, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall J","family":"Mack","sequence":"additional","affiliation":[{"name":"Recro Pharma Inc, Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart W","family":"McCallum","sequence":"additional","affiliation":[{"name":"Recro Pharma Inc, Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Du","sequence":"additional","affiliation":[{"name":"Clinical Statistics Consulting, Blue Bell, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Hobson","sequence":"additional","affiliation":[{"name":"Recro Pharma Inc, Malvern, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"2025101112173464000_44.3.360.1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1358\/dot.1997.33.10.451138","article-title":"Pharmacological, pharmacokinetic and clinical profile of meloxicam","volume":"33","author":"Degner","year":"1997","journal-title":"Drugs Today"},{"key":"2025101112173464000_44.3.360.2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00044011-200222120-00001","article-title":"Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug","volume":"22","author":"Del Tacca","year":"2002","journal-title":"Clin Drug Investig"},{"key":"2025101112173464000_44.3.360.3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcph.1058","article-title":"A randomized double-blind controlled trial of intravenous meloxicam in the treatment of pain following dental impaction surgery","volume":"58","author":"Christensen","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"2025101112173464000_44.3.360.4","doi-asserted-by":"crossref","unstructured":"Rechberger T , Mack RJ , McCallum SW , et al . Analgesic efficacy and safety of intravenous meloxicam in subjects with moderate-to-severe pain after open abdominal hysterectomy. Anesth Analg 2018. [Epub ahead of print 9 Nov 2018].doi:10.1213\/ANE.0000000000003920","DOI":"10.1213\/ANE.0000000000003920"},{"key":"2025101112173464000_44.3.360.5","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2147\/JPR.S163736","article-title":"Safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate to severe pain following laparoscopic abdominal surgery","volume":"11","author":"Singla","year":"2018","journal-title":"J Pain Res"},{"key":"2025101112173464000_44.3.360.6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/JPR.S149879","article-title":"Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy","volume":"11","author":"Gottlieb","year":"2018","journal-title":"J Pain Res"},{"key":"2025101112173464000_44.3.360.7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/AJP.0000000000000609","article-title":"Efficacy and safety of intravenous meloxicam in patients with moderate-to-severe pain following bunionectomy: a randomized, double-blind, placebo-controlled trial","volume":"34","author":"Pollak","year":"2018","journal-title":"Clin J Pain"},{"key":"2025101112173464000_44.3.360.8","doi-asserted-by":"crossref","DOI":"10.1097\/GOX.0000000000001846","article-title":"Efficacy and safety of intravenous meloxicam in subjects with moderate-to-severe pain following abdominoplasty","volume":"6","author":"Singla","year":"2018","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2025101112173464000_44.3.360.9","first-page":"57","article-title":"Safety and opioid use in a phase 3, placebo-controlled study of intravenous meloxicam following major surgery [abstract]","volume":"129","author":"Bergese","year":"2017","journal-title":"Postgrad Med"},{"key":"2025101112173464000_44.3.360.10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/JPR.S75160","article-title":"New insights into the use of currently available non-steroidal anti-inflammatory drugs","volume":"8","author":"Brune","year":"2015","journal-title":"J Pain Res"},{"key":"2025101112173464000_44.3.360.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.12.008"},{"key":"2025101112173464000_44.3.360.12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjmed.2004.03.012","article-title":"Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam","volume":"117","author":"Singh","year":"2004","journal-title":"Am J Med"},{"key":"2025101112173464000_44.3.360.13","doi-asserted-by":"publisher","DOI":"10.1097\/00003643-200312000-00005"},{"key":"2025101112173464000_44.3.360.14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/oxfordjournals.bja.a013395","article-title":"Effect of meloxicam on postoperative pain after abdominal hysterectomy","volume":"84","author":"Thompson","year":"2000","journal-title":"Br J Anaesth"},{"key":"2025101112173464000_44.3.360.15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijom.2006.01.026","article-title":"Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery","volume":"35","author":"Aoki","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"suppl 1","key":"2025101112173464000_44.3.360.16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/rheumatology\/35.suppl_1.56","article-title":"An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment","volume":"35 Suppl 1","author":"Bevis","year":"1996","journal-title":"Br J Rheumatol"},{"key":"2025101112173464000_44.3.360.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1997.tb00030.x"},{"key":"2025101112173464000_44.3.360.18","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.semarthrit.2016.07.008","article-title":"Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: a systematic review and meta-analysis","volume":"46","author":"Teerawattananon","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025101112173464000_44.3.360.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.946"},{"key":"2025101112173464000_44.3.360.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.937"},{"key":"2025101112173464000_44.3.360.21","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427060-00005"},{"key":"2025101112173464000_44.3.360.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-014-0225-9","article-title":"The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review","volume":"23","author":"Asghar","year":"2015","journal-title":"Inflammopharmacology"},{"key":"2025101112173464000_44.3.360.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.adaj.2015.07.020"},{"key":"2025101112173464000_44.3.360.24","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31823c1030"},{"key":"2025101112173464000_44.3.360.25","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/j.anclin.2017.01.018","article-title":"Essential elements of multimodal analgesia in enhanced recovery after surgery (ERAS) guidelines","volume":"35","author":"Beverly","year":"2017","journal-title":"Anesthesiol Clin"}],"container-title":["Regional Anesthesia & Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rapm-2018-100184","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:17:47Z","timestamp":1760210267000},"score":1,"resource":{"primary":{"URL":"https:\/\/rapm.bmj.com\/lookup\/doi\/10.1136\/rapm-2018-100184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,18]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/rapm-2018-100184"],"URL":"https:\/\/doi.org\/10.1136\/rapm-2018-100184","relation":{},"ISSN":["1098-7339","1532-8651"],"issn-type":[{"type":"print","value":"1098-7339"},{"type":"electronic","value":"1532-8651"}],"subject":[],"published":{"date-parts":[[2019,2,7]]}}}